Effects of N-acetylcysteine on asthma exacerbation

Iranian Journal of Allergy, Asthma and Immunology

Volumn 9, Issue 2, 2010, Pages 103-109

  Aliyali, Masoud ^a   Amiri, Ali Poorhasan ^b   Sharifpoor, Ali ^a   Zalli, Fatemeh ^b  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antioxidant; Asthma; Mucolytic; Mucus hypersecretion; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID DERIVATIVE; PLACEBO;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DRUG EFFICACY; DYSPNEA; FEMALE; HOSPITALIZATION; HUMAN; MALE; NIGHT SLEEP; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SPUTUM ANALYSIS; WHEEZING;

ACETYLCYSTEINE; ADULT; AGED; ASTHMA; FEMALE; HUMANS; MALE; MIDDLE AGED; SINGLE-BLIND METHOD;

EID: 77956868010     PISSN: 17351502     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Rogers DF. Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol 2004; 4(3):241-50.
2. Evans CM, Kim K, Tuvim MJ, Dickey BF. Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med 2009; 15(1):4-11.
3. Evans CM, Koo JS. Airway mucus: the good, the bad, the sticky. Pharmacol Ther 2009; 121(3):332-48.
4. Rogers DF. Physiology of airway mucus secretion and pathophysiology of hypersecretion. Respir Care 2007; 52(9):1134-46.
5. Cohn L. Mucus in chronic airway diseases: sorting out the sticky details. J Clin Invest 2006; 116(2):306-8.
6. Daviskans E, Anderson SD, Young IH. Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. Respirology 2007; 12(5):683-91.
7. Ercan H, Birben E, Dizdar EA, Keskin O, Karaaslan C, Soyer OU, et al. Oxidative stress and genetic and epidemiologic determinants of oxidant injury in childhood asthma. J Allergy Clin Immunol 2008; 118(5):1097-104.
8. Dut R, Dizdar EA, Birben E, Sackesen C, Soyer OU, Besler T, et al. Oxidative stress and its determinants in the airways of children with asthma. Allergy 2008; 63(12):1605-9.
9. Fujisawa T. Role of oxygen radicals on bronchial asthma. Curr Durg Targets Inflamm Allergy 2005; 4(4):505-9.
10. Misso NL, Thompson PJ. Oxidative stress and antioxidant deficiencies in asthma: potential modification by diet. Redox Rep 2005; 10(5):247-55.
11. Nadeem A, Masood A, Siddiqui N. Oxidant-antioxidant imbalance in asthma: scientific evidence, epidemiological data and possible therapeutic options. Ther Adv Respir Dis 2008; 2(4):215-53.
12. Suzuki S, Matsukura S, Takeuchi H, Kawaguchi M, Ieki K, Odaka M, et al. Increase in reactive oxygen metabolite level in acute exacerbations of asthma. Int Arch Allergy Immunol 2008; 146(suppl 1):67-72.
13. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125(1 Suppl):1S-39S.
14. Salathe M, O'Riordan TG, Wanner A. Treatment of mucociliary dysfunction. Chest 1996; 110(4):1048-57.
15. Rogers RM, Shuman JF, Zubrow AB. Bronchopulmonary lavage in bronchial asthma. Chest 1973; 63:Suppl:62S-4S.
16. Kupczvk M, Kuna P. Mucolytics in acute and chronic respiratory tract disorders: uses for treatment and antioxidant properties. Pol merkur Lekarski 2002; 12(69):248-52.
17. MacNee W. Oxidants/antioxidants and COPD. Chest 2000; 117(5 Suppl 1):303S-17S.
18. Spapen HD, Diltoer MW, Nguyen DN, Hendrickx I, Huyghens LP. Effects of N-acetylcysteine on microalbuminuria and organ failure in acute severe sepsis. Chest 2005; 127(4):1413-9.
19. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23(4):629-36.
20. Blesa S, Cortijo J, Mata M, Serrano A, Closa D, Santangelo F, et al. Oral N-acetylcysteine attenuates the rat pulmonary inflammatory response to antigen. Eur Respir J 2003; 21(3):394-400.
21. Gibson PG. Monitoring the patient with asthma: an evidence-based approach. J Allergy Clin Immunol 2000; 106(1 Pt 1):17-26.
22. Rogers DF. Mucoactive drugs for asthma and COPD: any place in therapy? Expert Opin Investig Drugs 2002; 11(1):15-35.
23. Morcillo EJ, Cortijo J. Mucus and MUC in asthma. Curr Opin Pulm Med 2006; 12(1):1-6.
24. Agrawal A, Mabalirajan U, Ram A, Ghosh B. Novel approaches for inhibition of mucus hypersecretion in asthma. Recent Pat Inflamm Allergy Drug Discov 2007; 1(3):188-92.
25. Hauber HP, Zabel P. Emerging mucus regulating drugs in inflammatory and allergic lung disease. Inflamm Allergy Drug Targets 2008; 7(1):30-4.
26. Rogers DF, Barnes PJ. Treatment of airway mucus hypersecretion. Ann Med 2006; 38(2):116-25.
27. Barnes PJ. Current and future therapies for airway mucus hypersecretion. Novartis Found Symp 2002; 248:237-49.
28. Williams OW, Sharafkhaneh A, Kim V, Dickey BF, Evans CM. Airway mucus: from production to secretion. Am J Respir Cell Mol Biol 2006; 34(5):527-36.
29. Aylward M, Maddock J, Dewland P. Clinical evaluation of acetylcysteine in the treatment of patients with chronic obsructive bronchitis: a balanced double-blind trial with placebo control. Eur J Respir Dis Suppl 1980; 111:81-9.
30. Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. Eur J Respir Dis 1980; 61:93-108.
31. Black PN, Morgan-Day A, McMillan TE, Poole PJ, Young RP. Randomized, controlled trial of N-acetylcysteine for treatment of acute exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med 2004; 4:13.
32. Bylin G, Hedenstierna G, Lagerstrand L, Wagner PD. No influence of acetylcysteine on gas exchange and spirometry in chronic asthma. Eur J Respir Dis 1987; 71(2):102-7.
33. Nadeem A, Raj HG, Chhabra SK. Increased oxidative stress in acuta exacerbations of asthma. J Asthma 2005; 42(1):45-50.
34. Nadeem A, Chhabra SK, Masood A, Raj HG. Increased oxidative stress and altered levels of antioxidants in asthma. J Allergy Clin Immunol 2003; 111(1):72-8.
35. Sugiura H, Ichinose M. Oxidative and nitrative stress in bronchial asthma. Antioxid Redox Signal 2003; 10(4):785-97.
36. Mak JC, Chan-Yeung MM. Reactive oxidant species in asthma. Curr Opin Pulm Med 2006; 12(1):7-11.
37. Lee Ks, Kim SR,Park HS, Park SJ, Min KH, Lee KY, et al. A novel thiol compound, N-acetylcysteine amide, attenuates allergic airway disease by regulating activation of NF-kappaB and hypoxia-inducible factor-1alpha. Exp Mol Med 2007; 39(6):756-68.
38. Wuyts WA, Vanaudenaerde BM, Dupont LJ, Demedts MG, Verleden GM. N-acetylcysteine reduces chemokine release via inhibition of p38 MAPK in human airway smooth muscle cells. Eur Respir J 2003; 22(1):43-9.
39. Cotgreave IA, Eklund A, Larsson K, Moldeus PW. No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. Eur J Respir Dis 1987; 70(2):73-7.
40. Barnes PJ. Reduced histone deacetylase in COPD: clinical implications. Chest 2006; 129(1):151-5.